Ocular Therapeutix Inc
OCUL12.100USD
-0.610-4.80%
收盘 09/19, 16:00（美东）报价延迟15分钟
2.09B总市值
亏损市盈率 TTM
关于 Ocular Therapeutix Inc 公司
Ocular Therapeutix, Inc. 是一家生物制药公司。该公司致力于开发和商业化治疗湿性老年性黄斑变性 (wet AMD)、糖尿病视网膜病变和其他眼部疾病和病症的疗法。其首款商业化药物产品 DEXTENZA 用于治疗眼科手术后的眼部炎症和疼痛以及与过敏性结膜炎相关的眼部瘙痒。该公司还在开发另外两种临床阶段资产，OTX-DED（地塞米松小管内插入物）用于短期治疗干眼症的体征和症状，OTX-CSI（环孢菌素小管内插入物）用于长期治疗干眼症。该公司正在进行一项关键的 III 期临床试验，以评估 AXPAXLI 对湿性 AMD 的治疗效果。其临床产品组合还包括 PAXTRAVA，该产品正处于 III 期临床开发阶段，用于治疗原发性开角型青光眼 (OAG) 或眼高压 (OHT)。
公司简介
公司代码OCUL
公司名称Ocular Therapeutix Inc
上市日期Jul 25, 2014
CEODr. Pravin U. Dugel, M.D.
员工数量274
证券类型Ordinary Share
年结日Jul 25
公司地址15 Crosby Drive
城市BEDFORD
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编01730
电话17813574000
网址https://www.ocutx.com/
公司代码OCUL
上市日期Jul 25, 2014
CEODr. Pravin U. Dugel, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Pravin U. Dugel, M.D.
Dr. Pravin U. Dugel, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
3.18M
-1.54%
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Chief Strategy Officer
Chief Strategy Officer
279.74K
-0.67%
Dr. Richard L. Lindstrom, M.D.
Dr. Richard L. Lindstrom, M.D.
Independent Director
Independent Director
174.70K
+8.71%
Mr. Charles M. Warden
Mr. Charles M. Warden
Lead Independent Director
Lead Independent Director
74.46K
+23.15%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
50.00K
+38.89%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
34.93K
+66.88%
Dr. Seung Suh Hong, Ph.D.
Dr. Seung Suh Hong, Ph.D.
Independent Director
Independent Director
34.93K
+66.88%
Mr. Donald D. Notman, Jr.
Mr. Donald D. Notman, Jr.
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Ms. Leslie J. Williams
Ms. Leslie J. Williams
Independent Director
Independent Director
--
--
Mr. Todd D.C. Anderman
Mr. Todd D.C. Anderman
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Pravin U. Dugel, M.D.
Dr. Pravin U. Dugel, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
3.18M
-1.54%
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Chief Strategy Officer
Chief Strategy Officer
279.74K
-0.67%
Dr. Richard L. Lindstrom, M.D.
Dr. Richard L. Lindstrom, M.D.
Independent Director
Independent Director
174.70K
+8.71%
Mr. Charles M. Warden
Mr. Charles M. Warden
Lead Independent Director
Lead Independent Director
74.46K
+23.15%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
50.00K
+38.89%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
34.93K
+66.88%
收入明细
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
63.72M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月15日 周五
更新时间: 8月15日 周五
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
10.67%
Deep Track Capital LP
8.22%
Summer Road, LLC
7.98%
VR Adviser, LLC
7.33%
BlackRock Institutional Trust Company, N.A.
5.37%
其他
60.43%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
10.67%
Deep Track Capital LP
8.22%
Summer Road, LLC
7.98%
VR Adviser, LLC
7.33%
BlackRock Institutional Trust Company, N.A.
5.37%
其他
60.43%
股东类型
持股股东
占比
Investment Advisor
33.92%
Hedge Fund
22.17%
Investment Advisor/Hedge Fund
21.92%
Venture Capital
8.60%
Individual Investor
3.37%
Research Firm
2.94%
Private Equity
0.77%
Bank and Trust
0.28%
Pension Fund
0.23%
其他
5.79%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
382
145.09M
83.39%
-6.62M
2025Q1
391
145.03M
91.13%
-3.83M
2024Q4
382
137.38M
86.40%
-14.17M
2024Q3
370
142.63M
91.08%
-5.76M
2024Q2
356
140.04M
90.02%
+6.94M
2024Q1
335
125.94M
81.55%
+41.06M
2023Q4
313
75.41M
65.72%
+26.62M
2023Q3
319
44.73M
56.36%
-8.88M
2023Q2
327
47.63M
60.14%
-3.66M
2023Q1
334
44.52M
57.43%
-7.38M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Deep Track Capital LP
14.29M
8.97%
+1.46M
+11.36%
Mar 31, 2025
Summer Road, LLC
13.88M
8.71%
+8.55K
+0.06%
Mar 31, 2025
VR Adviser, LLC
12.76M
8.01%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.81M
6.79%
+94.61K
+0.88%
Mar 31, 2025
The Vanguard Group, Inc.
8.34M
5.24%
-119.40K
-1.41%
Mar 31, 2025
Avoro Capital Advisors LLC
8.06M
5.06%
--
--
Mar 31, 2025
TCG Crossover Management, LLC
5.32M
3.34%
--
--
Mar 31, 2025
Citadel Advisors LLC
4.81M
3.02%
+354.30K
+7.95%
Mar 31, 2025
Adage Capital Management, L.P.
5.20M
3.26%
+1.60M
+44.44%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
Invesco Pharmaceuticals ETF
4.45%
SPDR S&P Pharmaceuticals ETF
2.47%
Invesco Dorsey Wright Healthcare Momentum ETF
2.26%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.53%
iShares U.S. Pharmaceuticals ETF
0.73%
Invesco Dorsey Wright SmallCap Momentum ETF
0.51%
First Trust Small Cap Growth AlphaDEX Fund
0.46%
ProShares Ultra Nasdaq Biotechnology
0.2%
Invesco Nasdaq Biotechnology ETF
0.18%
First Trust Small Cap Core Alphadex Fund
0.16%
查看更多
Invesco Pharmaceuticals ETF
占比4.45%
SPDR S&P Pharmaceuticals ETF
占比2.47%
Invesco Dorsey Wright Healthcare Momentum ETF
占比2.26%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.53%
iShares U.S. Pharmaceuticals ETF
占比0.73%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0.51%
First Trust Small Cap Growth AlphaDEX Fund
占比0.46%
ProShares Ultra Nasdaq Biotechnology
占比0.2%
Invesco Nasdaq Biotechnology ETF
占比0.18%
First Trust Small Cap Core Alphadex Fund
占比0.16%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
